drug trial
Eli Lilly gets European marketing authorisation for psoriasis drug
April 26, 2016EC, EU, Eli Lilly, drug trial, psoriasis, regulation
US pharma firm Eli Lilly and Co (NYSE: LLY) on Tuesday said the European Commission backed marketing authorisation for its …
US panel says Sarepta’s trial DMD drug not proven effective
April 26, 2016Manufacturing and Production, Research and Development DMD, US FDA, drug trial, sarepta
A US advisory committee has concluded Sarepta Therapeutics’ (Nasdaq: SRPT) trial drug to treat muscle wasting condition has not proved …
BioMarin announces positive data from early stage trials of haemophilia A gene therapy
April 21, 2016Research and Development BioMarin Pharmaceutical, Phase II, drug trial, haemophilia A gene therapy
BioMarin Pharmaceutical (Nasdaq: BMRN) said early-stage trials for its haemophilia A gene therapy showed encouraging data. Chief Medical Officer, Hank …
Bayer says its Xarelto shows lower risk of stroke, brain haemorrhage for irregular heart rhythm condition vs BMS’ Coumadin
April 19, 2016Manufacturing and Production, Research and Development Bayer, Bristol-Myers Squibb, anti blood-clot, drug trial
New trials for anti blood-clotting drug Xarelto (rivaroxaban) showed lower risk of stroke and haemorrhage in patients with irregular heart …
Bristol-Myers Squibb’s Opdivo shows positive results in early stage trials for advanced skin cancer
April 19, 2016Manufacturing and Production, Research and Development Bristol-Myers Squibb, drug trial, immuno-therapy, oncology, opdivo
New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …
Eli Lilly drops development of diabetes drug in Phase III
April 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial
US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
FDA rejects Chiasma’s new drug application for therapy to treat rare growth disorder
April 18, 2016Research and Development, Sales and Marketing Chiasma Inc, US FDA, drug trial, rare disease
Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …
Gilead Sciences says Phase III trials for chronic HBV drug meet primary endpoints
April 15, 2016Gilead Sciences, US FDA, chronic hepatitis B, drug trial
Biotech firm Gilead Sciences (NYSE: GILD) on Friday announced positive results from late-stage trials for its drug to treat chronic …
Repros Therapeutics says positive results from Phase II trial of uterine fibroids drug; shares jump
April 15, 2016Medical Communications, Research and Development Repros Therapeutics, Shares, US FDA, drug trial, uterine fibroids
Shares in Repros Therapeutics (Nasdaq: RPRX) surged to close over 18% Thursday after the company announced positive mid-stage trial results …
FDA staff raises doubts on efficacy, safety of Clovis’ trial drug for lung cancer, shares plunge
April 11, 2016AstraZeneca, Clovis Oncology, US FDA, drug trial, lung cancer, regulation, rociletinib
Shares in Clovis Oncology Inc (Nasdaq: CLVS) plunged to close down nearly 18% after the US regulators expressed doubts if …
GSK’s gene therapy for rare condition in children gets EMA backing
April 4, 2016Research and Development, Sales and Marketing ADA-SCID, European Medicines Agency, GlaxoSmithKline, Orphan Therapy, Rare Treatment, drug trial, gene therapy
UK drug major GlaxoSmithKline (LSE: GSK) has won marketing recommendation from European regulators for its first gene therapy to treat …
Janssen-Cilag’s HIV treatment gets NHS backing
March 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial
Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV. The company said following the …
Portola Pharma stock drops on dismal Phase III trial results for blood-clot drug
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing Portola Pharmaceuticals, blood clot drug, drug trial, phase III
Shares in Portola Pharmaceuticals (Nasdaq: PTLA) dropped after the company reported disappointing late-stage trial results for its blood clotting drug. …
Merck & Co says study shows significantly higher persistence for its arthritis drug Simponi
March 17, 2016Research and Development, Sales and Marketing Merck & Co, drug trial, research, rheumatoid arthritis
US pharma giant Merck & Co (NYSE: MRK) said its rheumatoid arthritis drug showed significantly higher persistence compared with other drugs …
Vitae Pharma soars on positive mid-stage trial results for psoriasis drug
March 17, 2016Business Services, Research and Development, Sales and Marketing Vitae Pharmaceuticals, drug trial, psoriasis, research
Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported mid-stage trials of its psoriasis …
Latest content
FibroFind appoints Lee Borthwick as CEO
